BRIEF-S Immo 9-month reveue up at 147.1 million euros

COPENHAGEN, Nov 29 Novo Nordisk's long-acting insulin blockbuster Tresiba has a safe cardiovascular profile and reduces episodes of severely low blood glucose levels in patients with type 2 diabetes, the Denmark-based company said on Tuesday.